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interferon–based regimens and changed the land-
scape of HCV treatment.5-7 However, due to the 
high cost of treatment with this novel therapy, it 
was limited to patients with advanced liver dis-
ease in a large majority of countries.8,9
Direct-acting antiviral–based regimens that 
are interferon-free for treatment of HCV in-
fection became available in Poland mid-2015. 
From the beginning, reimbursement had no 
limitations related to fibrosis or any other fac-
tors, which provided a unique possibility to fol-
low changes in patient profile and physicians’ 
Introduction Hepatitis C virus (HCV) infection 
is recognized by the World Health Organization 
as a major public health problem worldwide that 
affects 71 million people globally, including over 
3 million inhabitants of the European Union.1-3 
The most efficient way to reduce the infection 
burden, prevent spread of infection, and pro-
gression of the disease to liver cirrhosis and he-
patocellular carcinoma in individual patients is 
the identification of those infected and subse-
quent treatment.4 Introduction of highly effective 
and safe direct-acting antivirals (DAA) replaced 
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the disease characteristics, and treatment efficacy 
determined by sustained virologic response (SVR) 
defined as undetectable HCV RNA after at least 
12 weeks of post-treatment follow-up. Safety out-
comes, such as adverse events and laboratory ab-
normalities were also followed for 12 weeks ac-
cording to NFZ therapeutic program.
The results are expressed as number and per-
centage or median and interquartile range. P val-
ues of less than 0.05 were considered to be sig-
nificant. Comparisons between groups were per-
formed with nonparametric tests. Sustained vi-
rologic response was calculated as intent-to-treat 
(ITT) analysis and after exclusion of lost to fol-
low-up patients as a modified ITT (mITT). For 
continuous variables, the significance of differ-
ence was calculated by the Kruskal–Wallis test 
for multigroup comparisons and the Mann–Whit-
ney test for comparisons between 2 groups. For 
qualitative variables, a P value was calculated by 
the χ2 test or the Fisher exact test (as appropri-
ate in case of small group size). No corrections 
for multiple testing in post hoc analyses were ap-
plied. Statistical analyses were performed using 
GraphPad Prism 5.1 (GraphPad Software, Inc., La 
Jolla, California, United States).
Results The study population was sex-balanced 
with a small predominance of women, who were 
older than men. We observed reduction of age be-
tween the first and third time interval (TAbLE 1). 
Age distribution demonstrated a biphasic increase 
of treated patients with the first peak around age 
36 to 45 years predominant in men and the sec-
ond around age 51 to 70 mostly in women. In 
2015 to 2016 and in 2017, the second peak was 
dominant, whereas in 2018, the first peak was 
higher irrespective of sex (FIguRE 1). The majori-
ty of treated patients were overweight or obese 
(BMI >25), and the proportion of such patients 
decreased significantly in successive time inter-
vals from 62% to 52% (TAbLE 1). Prevalence of co-
morbidities, including the most frequent, hyper-
tension and diabetes, also decreased from 68.6% 
in 2015 to 2016 to 59.5% in 2018, and it was ac-
companied by a tendency for a reduction of the 
use of concomitant medications (TAbLE 1). Geno-
type 1b infection was the most prevalent, but in 
successive time intervals decreased significantly 
from 86.8% to 74.7% and was replaced by an in-
creasing number of patients infected with G1a, 
G3, and G4 (TAbLE 1).
As shown in TAbLE 2, severity of liver disease was 
measured mostly with transient or shear-wave 
elastography and the role of liver biopsy decreased 
from 27.7% in 2015 to 2016 to 8.2% in 2018. Ad-
vanced liver disease corresponding to the META-
VIR score F3 or F4 was noted in about 60% of pa-
tients treated in 2015 to 2016, and that number 
decreased in consecutive time intervals to 45% and 
26% (TAbLE 2). It was accompanied by some reduc-
tion in the number of patients with past or cur-
rent signs of hepatic decompensation, a decrease of 
patients with history of hepatocellular carcinoma, 
preferences regarding selection of therapeutic 
options. The only exception were patients in-
fected with HCV genotype 3 (G3), who consti-
tuted about 10% of the population, because of 
the lack of reimbursement for daclatasvir plus 
sofosbuvir. These patients were treated with 
sofosbuvir plus ribavirin with or without pe-
gylated interferon alfa until pangenotypic regi-
mens became available in 2018.10 The first real-
world data from studies on ombitasvir / parita-
previr / ritonavir ± dasabuvir and ledipasvir / so-
fosbuvir in HCV-infected patients, mostly with 
advanced liver disease, were published in 2016 
and demonstrated effectiveness and safety sim-
ilar to those observed in clinical trials.11,12
The EpiTer-2 study was initiated in 2015 to 
follow epidemiologic changes of HCV infection 
in Poland and its therapeutic implications relat-
ed to new treatment options. Initial data from 
the first year of the study were published in 2018 
and focused on the characteristics of the patient 
population and treatment effectiveness.13 Fur-
ther analysis included patients with cirrhosis, 
those infected with HCV G3, those who did not 
respond to triple therapy, and those who received 
retreatment due to failure to respond to geno-
type-specific DAA before access to pangenotyp-
ic regimens.14-17
Numerous large real-world studies on the ef-
fectiveness of different regimens in various pop-
ulations were carried out worldwide and pub-
lished recently.18-25 However, none of them, ex-
cept the German Hepatitis C-Registry, document-
ed and analyzed changes in populations of treat-
ed patients and their effect on effectiveness and 
safety of HCV therapy.25 The aim of the current 
EpiTer-2 analysis is to follow changes of patient 
characteristics and HCV treatment in a real-world 
setting during the initial 4 years of access to in-
terferon-free therapy.
Patients and methods EpiTer-2 is an investiga-
tor--initiated study, supported by the Polish As-
sociation of Epidemiologists and Infectiologists, 
which included 22 Polish centers involved in di-
agnosis and treatment of HCV-infected patients. 
The EpiTer2 database included 10 152 patients 
who started treatment for HCV infection in Po-
land between July 1, 2015 and December 31, 2018 
and had an efficacy evaluation report available by 
July 31, 2019. Data of consecutive patients treated 
in a therapeutic program reimbursed by the Pol-
ish National Health Fund (in Polish, Narodowy 
Fundusz Zdrowia [NFZ]) were collected retrospec-
tively with a web-based questionnaire. The regi-
men was selected based on the physician’s judg-
ment from available therapeutic options and ad-
ministered according to the protocol of the NFZ 
therapeutic program, product characteristics, and 
recommendations of the Polish Group of Experts 
for HCV.26,27 The analysis was carried out by com-
parison of 3 time intervals—first from 2015 to 
2016 (n = 2879), second in 2017 (n = 3349), and 
third 2018 (n = 3924)—with respect to patients, 
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predominant. However, in 2018, 77 retreated 
nonresponders to interferon-free regimens were 
registered, compared with 27 in 2015–2016 and 
2017 (TAbLE 3). In 2015 to 2016, almost two-thirds 
of patients received ombitasvir /paritaprevir / rito-
navir ± dasabuvir ± ribavirin, but in subsequent 
time intervals, this regimen was replaced in part 
by ledipasvir / sofosbuvir ± ribavirin and grazo-
previr / elbasvir ± ribavirin (TAbLE 3). Therapeutic 
options based on sofosbuvir, including pegylat-
ed interferon–containing therapy administered 
to G3-infected patients in 2015–2016 and 2017, 
were replaced by pangenotypic regimens in 2018. 
About 20% of patients who started therapy in 
2018 were treated with either velpatasvir / so-
fosbuvir ± ribavirin or glecaprevir / pibrentasvir.
Effectiveness of treatment in the whole popu-
lation, measured as ITT analysis, was 95%, but in 
the mITT it was 97%, and similar SVR rates were 
and an increasing proportion of patients with the 
Model for End-Stage Liver Disease (MELD) score 
below 15 and classified as Child-Pugh class A. Ad-
ditionally, the number of patients who had under-
gone liver transplantation decreased from 100 in 
2015–2016 to 3 in 2018 (TAbLE 2). As shown in TAbLE 2, 
there was a reduction of cryoglobulinemia frequen-
cy, but there were no changes in prevalence of oth-
er extrahepatic manifestations and hepatitis B vi-
rus coinfections. On the other hand, we observed 
an increase of HIV prevalence among all treated 
patients from 1.4% to 7.3%.
In 2015 to 2016, 53% of patients were re-
treated due to failure or discontinuation of pre-
vious therapy, whereas in 2017 and 2018, the 
proportion of these patients decreased signif-
icantly to 34% and 14%, respectively (TAbLE 3). 
Among retreated patients in all time intervals, 
those who failed interferon-based regimens were 
TAbLE 1 Characteristics of patients in 3 time intervals
Parameter 2015–2016 2017 2018 P value
Number of patients 2879 3349 3924 –
Sex Women 1473 (51) 1743 (52) 2022 (52) 0.78
Men 1403 (49) 1606 (48) 1902 (48)
Age, y, median (IQR) Both sexes 58 (46–65) 55 (41–63)a 49 (38–62)b <0.001
Women 60 (51–67) 58 (42–65)a 53 (38–65)b <0.001
Men 54 (42–62) 51 (39–61)a 46 (37–60)b <0.001
BMI, kg/m2 <18.5 35 (1.2) 55 (1.6) 73 (1.9) <0.001
18.5–25 1007 (35.0) 1335 (39.9)a 1721 (43.9)b
25–30 1245 (43.2) 1281 (38.3)a 1399 (35.7)c
>30 544 (18.9) 570 (17.0) 639 (16.3)
No data 48 (1.7) 108 (3.2)a 92 (2.3)c
HCV genotype 1a 60 (2.1) 97 (2.9) 180 (4.6)b <0.001
1b 2499 (86.8) 2640 (78.8)a 2931 (74.7)b
1 (no subgenotyping) 36 (1.3) 89 (2.7)a 73 (1.9)c
2 3 (0.1) 2 (0.1) 8 (0.2)
3 198 (6.9) 356 (10.6)a 510 (13.0)c
4 83 (2.9) 165 (4.9)a 220 (5.6)
5 0 0 0
6 0 0 2 (0.1)
Comorbidities Any comorbidity 1976 (68.6) 2268 (67.7) 2335 (59.5)b <0.001
Hypertension 1128 (39.2) 1210 (36.1)d 1191 (30.3)b <0.001
Diabetes 482 (16.7) 461 (13.8)a 384 (9.8)b <0.001
Renal insufficiency 121 (4.2) 204 (6.1)d 122 (3.1)b <0.001
Autoimmune disease 79 (2.7) 59 (1.8)d 85 (2.2) 0.03
Non-HCC tumors 58 (2.0) 57 (1.7) 72 (1.8) 0.66
Other 1369 (48.6) 1764 (52.7)a 1739 (44.3)b <0.001
Concomitant medications 1859 (64.6) 2131 (63.6) 2266 (57.7)b <0.001
Data are presented as number (percentage) unless otherwise indicated.
a 2015–2016 vs 2017, P <0.001
b 2017 vs 2018, P <0.001
c 2017 vs 2018, P <0.05
d 2015–2016 vs 2017, P <0.05
Abbreviations: BMI, body mass index; HCC, hepatocellular carcinoma; HCV, hepatitis C virus
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centers during the analyzed time interval, which 
started in mid-2015 with the introduction of the 
NFZ therapeutic program for viral hepatitis C pro-
viding reimbursement of interferon-free regimens 
without any fibrosis limitations. Since the Epi-
Ter-2 database includes 10 152 patients (36% of 
the whole population) from 22 treating centers, 
we can assume that sample is representative for 
the country. Due to the lack of official NFZ re-
ports on patients’ characteristics, treatment ef-
fectiveness and its safety, these data are the only 
source of information on changes in the popula-
tion of patients infected with HCV and treated 
in Poland. They are particularly useful to predict 
HCV elimination, which according to the recent 
estimations will not be possible without annu-
al screening of 2.5 to 3 million inhabitants and 
treatment of 12 thousand of those diagnosed.28 
Previously published analysis carried out in 2013 
to 2015 demonstrated G1b and G3 prevalence of 
82% and 11%, respectively.29 The current study 
showed a decrease of G1b frequency to 75% and 
its increase regarding other genotypes between 
2015 and 2018, which is similar to the findings 
of Huppe et al25 in a German population. It can 
be explained by access to highly effective inter-
feron-free genotype specific regimens adminis-
tered mostly to G1-infected patients. On the oth-
er hand, there was no reimbursement of the da-
clatasvir plus sofosbuvir regimen for G3, so the 
available options (sofosbuvir plus pegylated in-
terferon plus ribavirin and sofosbuvir plus riba-
virin) in this population were suboptimal.
The lower age of treated patients between the 
first and third time interval in our study was 
similar to the Hepatitis C-Registry population.25 
The irregularity in the age distribution noted af-
ter the first year of the study and visible in the 
noted in all time intervals. As shown in TAbLE 4, 
similar effectiveness of 98% (mITT) was observed 
in patients treated with the most frequently ad-
ministered regimens of ombitasvir / paritapre-
vir / ritonavir ± dasabuvir ± ribavirin, ledipas-
vir / sofosbuvir ± ribavirin, and grazoprevir / el-
basvir ± ribavirin, as well as pangenotypic thera-
py with glecaprevir / pibrentasvir. The most sta-
ble effectiveness of 98% (mITT) across successive 
years was demonstrated in the biggest group of 
patients infected with G1b. On the other hand, 
the lowest SVR rate was observed among those 
infected with G3, but effectiveness improved sig-
nificantly (P = 0.004) from 87% to 94% (FIguRE 2). 
As shown in FIguRE 3, the SVR rate was similar in 
patients without cirrhosis irrespective of the time 
interval (97%–99%). In patients with cirrhosis, it 
was 96% in 2015 to 2016 and decreased to 94%, 
but the difference was not significant (FIguRE 3).
Analysis of the safety profile demonstrated 
a reduction in the prevalence of adverse events 
from 32.5% in 2015 to 2016 to 18.1% in 2018. 
The same tendency was observed regarding seri-
ous adverse events, deaths, and treatment discon-
tinuations (TAbLE 5). The most frequently reported 
adverse events were weakness or fatigue, head-
ache, and pruritus. Both adverse events and lab-
oratory abnormalities were infrequent and mild 
(TAbLE 5). Decreasing prevalence of safety issues 
in successive time intervals was accompanied by 
reduced frequency of regimens containing riba-
virin (TAbLE 3). This tendency was observed most-
ly in patients receiving interferon-free regimens, 
which demonstrated decline of ribavirin use from 
44.6% (2015–2016) to 10.6% (2018).
Discussion About 28 thousand patients were 
treated for HCV infection in more than 60 Polish 
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TAbLE 2 Characteristics of liver disease in 3 time intervals
Parameter 2015–2016 2017 2018 P value
Liver fibrosis assessment Biopsy 798 (27.7) 599 (17.9)a 322 (8.2)b <0.001
TE 1613 (56) 2023 (60.4)a 2509 (63.9)c
SWE 394 (13.7) 657 (19.6)a 1080 (27.5)b
ARFI 7 (0.2) 21 (0.6)d 2 (0.1)b
No assessment 67 (2.3) 49 (1.5)d 11 (0.3)b
Fibrosis (METAVIR score) F0 13 (0.5) 28 (0.8) 122 (3.1)b <0.001
F1 611 (21.2) 1109 (33.1)a 1890 (48.2)b
F2 388 (13.5) 644 (19.2)a 874 (22.3)c
F3 460 (16) 640 (19.1)d 441 (11.2)b
F4 1254 (43.6) 870 (26)a 581 (14.8)b
Unknown 153 (5.3) 58 (1.7)a 16 (0.4)b
History of hepatic decompensation Ascites 164 (5.7) 86 (3)a 72 (2.2)c <0.001
Hepatic encephalopathy 56 (1.9) 21 (1)a 22 (1) <0.001
Documented esophageal varices 519 (18) 294 (8.8)a 141 (3.6)b <0.001
Hepatic decompensation at 
baseline
Moderate ascites (responded to 
diuretics)
59 (2.0) 36 (1.1) 35 (0.9) 0.25
Tense ascites (did not respond to 
diuretics)
4 (0.1) 0 3 (0.1)
Hepatic encephalopathy, grade 1–2 38 (1.3) 17 (0.5) 12 (0.3) 0.69
Hepatic encephalopathy, grade 3–4 1 (0.03) 0 0
MELD <15 2578 (89.5) 3123 (93.3)a 3781 (96.4)b <0.001
15–18 76 (2.5) 55 (1.6)d 65 (1.7)
19–20 29 (1) 55 (1.6)d 28 (0.7)b
>20 25 (0.9) 21 (0.6) 31 (0.8)
No data 171 (5.9) 95 (2.8)a 19 (0.5)b
Child-Pugh class A 2592 (90) 3150 (94.1)a 3828 (97.6)b <0.001
B 150 (5.6) 98 (2.9)a 74 (1.9)#
C 12 (0.4) 1 (0.03)d 3 (0.08)
No data 115 (4) 100 (3)d 19 (0.5)b
History of HCC 91 (3.2) 60 (1.8)a 28 (0.7)b <0.001
History of liver transplantation 100 (3.5) 42 (1.3)a 3 (0.08)b <0.001
Extrahepatic manifestations of HCV 
infection
Cryoglobulinemia 197 (6.8) 227 (6.8) 177 (4.5)b 0.005
Thyroid abnormalities with 
antithyroid antibodies
39 (1.4) 30 (0.9) 38 (1)c
Thrombocytopenia with or without 
cirrhosis and splenomegaly
15 (0.5) 18 (0.5) 37 (0.9)
Other 24 (0.8) 24 (0.7) 24 (0.6)
HIV coinfections 41 (1.4) 132 (3.9)a 287 (7.3)b <0.001
HBV coinfections Reported coinfection 288 (10) 538 (16.1)a 523 (13.3)c <0.001
HBV DNA (+) 11 (0.4) 22 (0.7) 19 (0.5) 0.3
HBsAg (+) 28 (1) 42 (1.3) 41 (1) 0.53
Anti-HBc total (+) 269 (9.3) 516 (15.4)a 514 (13.1)c <0.001
Data are presented as number (percentage).
a 2015–2016 vs 2017, P <0.001
b 2017 vs 2018, P <0.001
c 2017 vs 2018, P <0.05
d 2015–2016 vs 2017, P <0.05
Abbreviations: anti-HBc, antibodies against hepatitis B core antigen; ARFI, acoustic radiation force impulse; HBsAg, hepatitis B surface antigen; 
HBV, hepatitis B virus; HCV, hepatitis C virus; MELD, Model for End-Stage Liver Disease; SWE, shear-wave elastography; TE, transient elastography; 
others, see TAbLE 1
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TAbLE 3 Treatment characteristics in 3 time intervals (table footnotes on the next page)
Parameter 2015–2016 2017 2018 P value
Treatment history
Naïve 1338 (46.5) 2226 (66.5)a 3346 (85.3)b <0.001
Relapse 405 (14.5) 322 (9.6)a 211 (5.4)b
Null response 571 (19.8) 361 (10.8)a 187 (4.8)b
Discontinuation for safety reasons 181 (6.3) 142 (4.2)a 61 (1.6)b
Nonresponse – type unknown 373 (12.9) 280 (8.4)a 107 (2.7)b
Unknown history 13 (0.5) 18 (0.5) 12 (0.3)
Previous regimen in patients with treatment failure
Number of patients with treatment failure 1530 1105 566 –
PegIFN + RBV 1091 (71.3) 891 (80.6)a 416 (73.5)c <0.001
TVR + PegIFN + RBV 181 (11.8) 49 (4.4)a 4 (0.7)b
BOC + PegIFN + RBV 108 (7.1) 30 (2.7)a 10 (1.8)
IFNnat + RBV 71 (4.6) 29 (2.6)d 2 (0.4)b
IFNalfa + RBV 29 (1.9) 45 (4.1)d 6 (1.1)b
SMV + PegIFN + RBV 26 (1.7) 34 (3.1)d 15 (2.7)
SOF + PegIFN + RBV 4 (0.3) 3 (0.3) 18 (3.2)b
IFN-free 10 (0.7) 17 (1.5)d 77 (13.6)b
Other IFN-containing and unknown 10 (0.7) 7 (0.6) 18 (3.2)b
Current treatment regimen
OBV / PTV / r + DSV, 8 weeks 2 (0.07) 1852 
(64.3)





OBV / PTV / r + DSV, 12 weeks 1029 (35.7) 1021 (30.5) 364 (9.3)
OBV / PTV /r + DSV + RBV, 12 weeks 711 (24.7) 112 (3.3) 37 (0.9)
OBV / PTV / r + DSV + RBV, 24 weeks 34 (1.2) 22 (0.7) 0
OBV / PTV / r + RBV, 12 weeks 42 (1.5) 103 (3.1) 75 (1.9)
OBV / PTV / r + RBV, 24 weeks 34 (1.2) 7 (0.2) 0





LDV / SOF, 12 weeks 193 (6.7) 483 (14.5) 568 (14.5)
LDV / SOF, 24 weeks 76 (2.6) 53 (1.6) 25 (0.6)
LDV / SOF + RBV, 12 weeks 317 (11.0) 299 (8.9) 126 (3.2)
LDV / SOF + RBV, 24 weeks 47 (1.6) 12 (0.4) 4 (0.1)





SOF + RBV, 24 weeks 74 (2.6) 199 (5.9) 56 (1.4)
SOF + DCV ± RBV, 24 weeks 12 (0.4) 29 (0.9) 11 (0.3)
SOF + SMV ± RBV, 12 weeks 10 (0.4) 0 0





GZR / EBR +vRBV, 16 weeks 0 16 (0.5) 34 (0.9)





SOF / VEL + RBV, 12 weeks 0 0 43 (1.1)
SOF / VEL ± RBV, 24 weeks 0 0 24 (0.6)





GLE / PIB, 12 weeks 0 0 97 (2.5)
GLE / PIB, 16 weeks 0 0 27 (0.7)
DCV + SMV + RBV 3 (0.1) 96 (3.3) 0 41a (1.2) 0 0 <0.001
DCV + ASV, 24 weeks 93 (3.2) 41 (1.2) 0
SOF + PegIFN + RBV, 12 weeks 101 (3.5) 130 
(4.5)





TVR + PegIFN + RBV 3 (0.1) 0 0
SMV + PegIFN + RBV 7 (0.2) 2 (0.1) 0
PegIFN + RBV, 24 weeks 19 (0.7) 4 (0.12) 0
Other 10 (0.4) 10 (0.3) 8 (0.2) 8 (0.2) 2 (0.05) 2 (0.05) 0.02
RBV-containing therapies 1417 (49.2) 928 (27.7)a 477 (12.2)b <0.001
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TAbLE 4 Treatment effectiveness according to regimen, calculated as ITT and mITT analysis, which included all 
therapeutic options administered to at least 10 patients
Regimen SVR, ITTa, % (n / N) SVR, mITTb, % (n / N)
All regimens 95 (9614/10152) 97 (9614/9883)
OBV / PTV / r ± DSV ± RBV
Total 97 (1918/4052) 98 (3918/3986)
OBV / PTV / r + DSV 8 weeks 96 (442/459) 97 (442/457)
12 weeks 97 (2348/2415) 99 (2348/2378)
OBV / PTV / r + DSV + RBV 12 weeks 96 (824/860) 98 (824/842)
24 weeks 91 (52/57) 98 (52/53)
OBV / PTV / r + RBV 12 weeks 96 (212/220) 98 (212/216)
24 weeks 98 (40/41) 100 (40/40)
LDV / SOF ± RBV
Total 95 (2680/2811) 98 (2680/2730)
LDV / SOF 8 weeks 97 (577/595) 99 (577/583)
12 weeks 96 (1201/1254) 98 (1201/1220)
24 weeks 92 (141/154) 99 (141/143)
LDV / SOF + RBV 12 weeks 94 (702/745) 97 (702/727)
24 weeks 94 (59/63) 95 (59/62)
GZR / EBR ± RBV
Total 95 (1542/1616) 98 (1542/1570)
GZR / EBR ± RBV 12 weeks 95 (1489/1560) 98 (1489/1517)
16 weeks 95 (53/56) 100 (53/53)
VEL / SOF ± RBV
Total 88 (376/425) 95 (376/397)
VEL / SOF 12 weeks 91 (323/356) 98 (323/331)
VEL / SOF + RBV 12 weeks 76 (34/45) 76 (34/45)
24 weeks 79 (19/24) 90 (19/21)
GLE / PIB
Total 96 (364/380) 98 (364/371)
GLE / PIB 8 weeks 96 (244/255) 98 (244/249)
12 weeks 97 (94/97) 100 (94/94)
16 weeks 93 (26/28) 93 (26/28)
Other regimens
DCV + ASV, 24 weeks 88 (119/135) 90 (119/132)
SOF + RBV, 24 weeks 79 (364/463) 85 (364/427)
SOF + DCV ± RBV, 24 weeks 91 (39/43) 98 (39/40)
SOF + SMV ± RBV, 12 weeks 90 (9/10) 90 (9/10)
SOF + PegIFN + RBV, 12 weeks 91 (395/435) 93 (395/427)
a Analysis included all patients receiving at least 1 dose of the treatment
b Analysis excluded patients with missing data of sustained virologic response (12 or 24 weeks after treatment 
completion)
Abbreviations: ITT, intent-to-treat analysis; mITT, modified intent-to-treat analysis; others, see TAbLE 3
TAbLE 3 Treatment characteristics in 3 time intervals (footnotes to the table on the previous page)
Data are presented as number (percentage).
a 2015–2016 vs 2017, P <0.001
b 2017 vs 2018, P <0.001
c 2017 vs 2018, P <0.05
d 2015–2016 vs 2017, P <0.05
Abbreviations: ASV, asunaprevir; BOC, boceprevir; DCV, daclatasvir; DSV, dasabuvir; EBR, elbasvir; GLE, glecaprevir; GZR, grazoprevir; IFN, interferon; 
LDV, ledipasvir; OBV, ombitasvir; PegIFN, pegylated interferon; PIB, pibrentasvir; PTV / r, paritaprevir boosted ritonavir; RBV, ribavirin; SMV, simeprevir; 
SOF, sofosbuvir; TVR, telaprevir; VEL, velpatasvir
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and comedication. Despite a decline in comor-
bidities frequency, there is stable prevalence of 
autoimmune diseases which can still be activat-
ed even during interferon-free therapy.31 Com-
pared with previous studies carried out in Po-
land before 2018, the most visible is the decline 
of the proportion of patients with cirrhosis, par-
ticularly those with decompensation, hepatocel-
lular carcinoma, or liver transplantation histo-
ry.11-15 This tendency is what we expected from 
efficient HCV therapy—to cure patients in early 
phase of the infection and prevent progression to 
liver cirrhosis and hepatocellular carcinoma. As 
demonstrated previously, treatment of patients 
with advanced liver disease is sometimes intro-
duced too late to reverse development of hepa-
tocellular carcinoma.32
In 2015–2016, the majority of patients were 
treatment-experienced, whereas in 2018, previ-
ous therapy was reported only in 15%. In all 3 time 
intervals, a large majority (71%–81%) of retreat-
ed patients failed dual therapy with pegylated in-
terferon plus ribavirin. However, the proportion 
of previous failures for interferon-free regimens 
increased from 0.7% in 2015 to 2016 to 13.6% 
in 2018. Patients were treated according to the 
NFZ protocol that is based on drugs’ character-
istics and recommendations of the Polish Group 
2-peak pattern, with predominant age group be-
tween 56 and 65 years in the second peak, was 
currently confirmed and seems to be specific for 
the Polish population.13 However, in 2018, the 
first peak population aged between 36 and 45 
years became dominant and the majority of pa-
tients in this group were men. Interestingly, ac-
cording to the recently published data, the ma-
jority of HIV-coinfected patients in Poland are 
men of this age group, therefore, a conclusion 
can be made that, at least in part, male sex and 
drug use at the end of the 20th century could be 
responsible for the higher number of those treat-
ed aged 36 to 45 years.30 The reason of young-
er age in 2018 is priority given at the beginning 
of DAA era to patients with more advanced liv-
er disease, who were usually older. Until 2018, 
treating centers enrolled patients from waiting 
lists, so age distribution and disease advancement 
were not affected by the national screening pro-
gram, which will hopefully start in 2020. There 
were no changes in access to treatment for drug 
users, so it also does not affect age distribution. 
Generally speaking, patients receiving treatment 
for HCV infection during the analyzed time in-
terval became healthier, which was demonstrat-
ed through the reduced proportion of advanced 
liver disease, as well as decrease of comorbidities 
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in those infected with other genotypes. Howev-
er, it seems that access to pangenotypic regimens 
improved the SVR rate in this population in 2018. 
Interestingly, overall effectiveness of treatment 
analyzed in 2612 patients with cirrhosis was re-
duced to 95%. Safety profile of the therapies im-
proved in subsequent time intervals, which was 
the result of changes in patient characteristics, 
shortening of treatment, and reduced use of riba-
virin responsible for a number of adverse events, 
particularly in the first time interval. A decrease 
in the frequency of weakness or fatigue, pruritus, 
anemia, and hyperbilirubinemia is a result of less 
frequent ribavirin administration.
In conclusion, data collected in this long-
term study carried out in a real-world settings 
demonstrate significant changes in characteris-
tics of treated patients compared with the ini-
tial time interval when interferon-free regimens 
became available. These patients are younger, 
mostly treatment naïve, have less advanced dis-
ease, and fewer comorbidities and comedica-
tions. Together with shortening of treatment 
and ribavirin elimination, it resulted in improve-
ment of safety. On the other hand, changing reg-
imens during the 4-year interval did not influ-
ence the effectiveness, which remained at the 
level of 97%.
of Experts for HCV.26,27 Selection of the regimen 
for a particular patient among available thera-
peutic options was based on the physician’s judg-
ment. In 2015 to 2016, almost two-thirds of pa-
tients were treated with ombitasvir / paritapre-
vir / ritonavir ± dasabuvir ± ribavirin, but in subse-
quent time intervals, prescribed regimens became 
much more diverse, which was a consequence of 
competition and finally availability of pangeno-
typic regimens at the end of 2018.
Effectiveness of treatment with the most fre-
quently administered regimens in the analyzed 
time interval was very high and similar to that 
demonstrated in other large real-world experience 
studies.18-25 The only surprising exception was the 
relatively low SVR rate after treatment with sofos-
buvir / velpatasvir, which improved after exclusion 
of patients lost to follow-up. This phenomenon 
needs further analysis with a greater number of 
patients on this regimen included in the future. 
On the other hand, we observed, similar to pre-
vious publications, a relatively high response rate 
to the last available interferon-based regimen, so-
fosbuvir plus pegylated interferon plus ribavirin, 
which was dominant in Poland for G3 infections 
until mid-2018.14,33,34 Effectiveness of treatment 
was stable across genotypes and fibrosis except in 
patients infected with G3, which was lower than 
TAbLE 5 The most frequent (>1%) adverse events, laboratory abnormalities, and other treatment safety measures 
in 3 time intervals
Parameter 2015–2016 (n = 2879) 2017 (n = 3349) 2018 (n = 3924) P value
Adverse events 937 (32.5) 756 (22.6)a 710 (18.1)b <0.001
Serious adverse events 89 (3.1) 21 (0.6)a 38 (1) <0.001
Deaths 23 (0.8) 14 (0.4) 17 (0.4) <0.001
Treatment discontinuations 68 (2.4) 43 (1.3)c 29 (0.8)d <0.001
Most frequent adverse events (>1%)
Weakness/fatigue 442 (15.4) 345 (10.3)a 319 (8.1)d <0.001
Headache 99 (3.4) 97 (2.9) 124 (3.2) 0.47
Pruritus 108 (3.8) 85 (2.5)c 47 (1.2)b <0.001
Sleep disorders 90 (3.2) 71 (2.1)c 81 (2.1) 0.009
Myalgia / arthralgia 40 (1.4) 73 (2.2) 66 (1.7) 0.05
Nausea 62 (2.2) 45 (1.3)c 43 (1.1) 0.001
Abdominal pain 44 (1.5) 39 (1.2) 46 (1.2) 0.34
Skin lesions 49 (1.7) 35 (1)c 27 (0.7) <0.001
Laboratory abnormalities
Anemia, G ≥2 174 (6) 144 (4.3)c 59 (1.5)b <0.001
Neutropenia, G ≥2 9 (0.3) 10 (0.3) 4 (0.1) 0.11
Thrombocytopenia, G ≥2 8 (0.3) 15 (0.5) 6 (0.15) 0.06
Hyperbilirubinemia, G ≥2 90 (3.1) 49 (1.5)a 15 (0.4)a <0.001
Elevation of 
aminotransferases, G ≥2
25 (0.9) 9 (0.3)c 4 (0.1) <0.001
Data are presented as number (percentage).
a 2015–2016 vs 2017, P <0.001
b 2017 vs 2018, P <0.001
c 2015–2016 vs 2017, P <0.05
d 2017 vs 2018, P <0.05
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